These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 16042992)
1. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Zaltzman R; Alexandrovich A; Trembovler V; Shohami E; Gozes I Peptides; 2005 Aug; 26(8):1520-7. PubMed ID: 16042992 [TBL] [Abstract][Full Text] [Related]
2. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Gozes I; Zaltzman R; Hauser J; Brenneman DE; Shohami E; Hill JM Curr Alzheimer Res; 2005 Apr; 2(2):149-53. PubMed ID: 15974912 [TBL] [Abstract][Full Text] [Related]
3. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. Beni-Adani L; Gozes I; Cohen Y; Assaf Y; Steingart RA; Brenneman DE; Eizenberg O; Trembolver V; Shohami E J Pharmacol Exp Ther; 2001 Jan; 296(1):57-63. PubMed ID: 11123362 [TBL] [Abstract][Full Text] [Related]
4. Activity-dependent neuroprotective protein: from gene to drug candidate. Gozes I Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064 [TBL] [Abstract][Full Text] [Related]
5. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. Romano J; Beni-Adani L; Nissenbaum OL; Brenneman DE; Shohami E; Gozes I J Mol Neurosci; 2002; 18(1-2):37-45. PubMed ID: 11931348 [TBL] [Abstract][Full Text] [Related]
6. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216 [TBL] [Abstract][Full Text] [Related]
7. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885 [TBL] [Abstract][Full Text] [Related]
8. Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. Stahel PF; Shohami E; Younis FM; Kariya K; Otto VI; Lenzlinger PM; Grosjean MB; Eugster HP; Trentz O; Kossmann T; Morganti-Kossmann MC J Cereb Blood Flow Metab; 2000 Feb; 20(2):369-80. PubMed ID: 10698075 [TBL] [Abstract][Full Text] [Related]
9. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Leinhase I; Schmidt OI; Thurman JM; Hossini AM; Rozanski M; Taha ME; Scheffler A; John T; Smith WR; Holers VM; Stahel PF Exp Neurol; 2006 Jun; 199(2):454-64. PubMed ID: 16545803 [TBL] [Abstract][Full Text] [Related]
11. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model. Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721 [TBL] [Abstract][Full Text] [Related]
12. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Mandel S; Rechavi G; Gozes I Dev Biol; 2007 Mar; 303(2):814-24. PubMed ID: 17222401 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Sokolowska P; Passemard S; Mok A; Schwendimann L; Gozes I; Gressens P Neuroscience; 2011 Jan; 173():156-68. PubMed ID: 21073926 [TBL] [Abstract][Full Text] [Related]
14. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Gozes I Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875 [TBL] [Abstract][Full Text] [Related]
15. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. Zemlyak I; Manley N; Vulih-Shultzman I; Cutler AB; Graber K; Sapolsky RM; Gozes I J Neurochem; 2009 Dec; 111(5):1252-63. PubMed ID: 19799711 [TBL] [Abstract][Full Text] [Related]
16. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Shiryaev N; Pikman R; Giladi E; Gozes I Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979 [TBL] [Abstract][Full Text] [Related]
17. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Dresner E; Agam G; Gozes I Eur Neuropsychopharmacol; 2011 May; 21(5):355-61. PubMed ID: 20598862 [TBL] [Abstract][Full Text] [Related]
19. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice. Thompson SN; Gibson TR; Thompson BM; Deng Y; Hall ED Exp Neurol; 2006 Sep; 201(1):253-65. PubMed ID: 16814284 [TBL] [Abstract][Full Text] [Related]
20. NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model. Van Dijck A; Van Dam D; De Deyn PP Peptides; 2009 Dec; 30(12):2480-2. PubMed ID: 19664667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]